Testing dolutegravir and rilpivirine in HIV-positive children
Part of Immune system & allergy, Infections clinical trials.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 6 to under 12 years old when signing consent
- Your child weighs at least 25 kilograms
- Your child has confirmed HIV infection and their HIV level is very low at screening
- Your child must have stayed on the same HIV medicine regimen for the last 6 months
- Your child has recent proof their HIV level stays below the test’s detection limit (or close to it based on timing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.